RYZB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RYZB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
RayzeBio's yield on cost for the quarter that ended in Sep. 2023 was 0.00.
The historical rank and industry rank for RayzeBio's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, RayzeBio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, RayzeBio's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where RayzeBio's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of RayzeBio is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
RayzeBio (NAS:RYZB) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of RayzeBio's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Hauwermeiren Timothy Van | director | C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Maha Katabi | director | SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Viking Global Opportunities Drawdown Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Drawdown Portfolio Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Arvind Kush | officer: Chief Financial Officer | C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121 |
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p. | 10 percent owner | 280 CONGRESS STREET, BOSTON MA 02210 |
Versant Ventures Vii Gp-gp, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Ventures Vii Gp, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Kenneth Song | director, officer: President and Chief Executive | C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121 |
Susan Moran | officer: Chief Medical Officer | 1232 RICHARDSON AVE, LOS ALTOS CA 94024 |
Venbio Global Strategic Gp Iii, L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Venbio Global Strategic Gp Iii, Ltd | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158 |
Venbio Global Strategic Fund Iii, L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Redmile Biopharma Investments Ii, L.p. | 10 percent owner | LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129 |
From GuruFocus
By Business Wire • 12-31-2023
By Marketwired • 11-06-2023
By Marketwired • 11-01-2023
By Business Wire • 09-19-2023
By PRNewswire • 01-13-2024
By PRNewswire • 12-26-2023
By Marketwired • 10-18-2023
By Business Wire • 09-14-2023
By Business Wire • 12-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.